Consistent with our findings, patients with renal glucosuria also display delayed growth and shortened stature.(16) In a different model of Sglt2 deletion, 50‐week‐old “Jimbee” male mice also exhibited reductions in body weight and lower tissue mineral density of both cortical and trabecular bone sites.(27) In contrast to our study and the “Jimbee” mice, a prior study in healthy mice treated with canagliflozin did not show reductions in cortical or trabecular BMD.(39) A bone phenotype was observed in a type 1 diabetes mellitus (T1DM) mouse model treated with canagliflozin. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.